● Recruiting

Hemorrhagic Brainstem Cavernous Malformations Treatment With Sirolimus: aSingle Centre, Randomized, Placebo-controlled Pilot Trial

Condition: Cavernous Malformations · Intracerebral Hemorrhage · Brainstem Stroke · Sponsor: Huashan Hospital

PhasePhase 2

Planned participants75

Who can joinAll sexes, 18 Years to 65 Years

Healthy volunteersNo

About this study

The aim of this pilot phase trial is to assess the safety and tolerability, and estimate the efficacy of sirolimus in reducing the incidence of ICH during high-risk periods for rebleeding, compared to placebo. This pilot trial will inform the design of a future definitive clinical trial on sirolimus treatment for CCM.

This description comes directly from the study's public registry record.

Talk to the study team

Zongze Li, Doctor · +8613121226581 · lizongze666@aliyun.com

Wei Zhu, Doctor · +8613121226581 · drzhuwei@fudan.edu.cn

Always discuss trial participation with your own doctor first.

Locations (2)

Huashan Hospital, Fudan University	Shanghai, Shanghai Municipality, China	Active Not Recruiting
Huashan Hospital, Fudan University	Shanghai, Shanghai Municipality, China	Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06091332